Residual Thrombosis: Still Relevant in the Direct Oral Anticoagulant (DOAC) Era?

Cecilia Becattini; Giancarlo Agnelli

doi:10.1055/a-2102-0376

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2023; 123(08): 747-749
DOI: 10.1055/a-2102-0376

Invited Editorial Focus

Residual Thrombosis: Still Relevant in the Direct Oral Anticoagulant (DOAC) Era?

Authors

Cecilia Becattini

¹Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, Perugia, Italy
Giancarlo Agnelli

¹Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, Perugia, Italy

Abstract

Full Text

References

References
1 Boutitie F, Pinede L, Schulman S. et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342: d3036
2 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
3 Mazzolai L, Ageno W, Alatri A. et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol 2022; 29 (08) 1248-1263
4 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
5 Zhang YJ, Li ZH, Shen D. et al. Association of combined lifestyle and polygenetic risk with incidence of venous thromboembolism: a large population-based cohort study. Thromb Haemost 2022; 122 (09) 1549-1557
6 Florin J, Stalder O, Baumgartner C, Méan M, Rodondi N, Aujesky D. Do patients with a family or personal history of venous thromboembolism have an increased risk of recurrence?. Thromb Haemost 2022; 122 (06) 1017-1026
7 Noumegni SR, Mansourati V, Tromeur C. et al. Risk factors of cardiovascular death after venous thromboembolism: results from a prospective cohort study. Thromb Haemost 2022; 122 (10) 1744-1756
8 Khan F, Tritschler T, Kimpton M. et al; MAJESTIC Collaborators. Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism : a systematic review and meta-analysis. Ann Intern Med 2021; 174 (10) 1420-1429
9 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
10 Prandoni P, Prins MH, Lensing AW. et al; AESOPUS Investigators. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150 (09) 577-585
11 Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 2000; 356 (9225): 182-183
12 Iding AFJ, Kremers BMM, Pallares Robles A, Ten Cate H, Ten Cate-Hoek AJ. Residual venous obstruction as an indicator of clinical outcomes following deep vein thrombosis: a management study. Thromb Haemost 2023; 123 (08) 763-772
13 Donadini MP, Ageno W, Antonucci E. et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost 2014; 111 (01) 172-179
14 Khan F, Rahman A, Carrier M. et al; MARVELOUS Collaborators. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366: l4363
15 Palareti G, Poli D, Ageno W. et al. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. Blood Adv 2022; 6 (23) 6005-6015
16 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
17 van de Brug A, de Winter MA, Ten Wolde M, Kaasjager K, Nijkeuter M. Deciding on treatment duration for unprovoked venous thromboembolism: what is important to patients?. Thromb Haemost 2022; 122 (04) 600-610